Checkpoint Therapeutics , Inc. (NASDAQ:CKPT), trading near its 52-week high of $4.50 with a market capitalization of $350 million, announced today that the waiting period under the Hart-Scott-Rodino ...
Checkpoint Therapeutics , Inc. (NASDAQ:CKPT), a biopharmaceutical company with a market capitalization of $354 million, held a special meeting on May 28, 2025, where shareholders voted on proposals ...
In December 2024, Checkpoint announced that the U.S. Food and Drug Administration (“FDA”) approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback